Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06042517 · ClinicalTrials.gov registry record · NA
Mechanisms of Ultrasound Neuromodulation Effects in Diabetes
A NA study of Insulin Sensitivity, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT06042517: Recruiting NA study of Insulin Sensitivity, sponsored by Yale University.
NCT06042517 is a NA study of Insulin Sensitivity that is actively recruiting participants, run by Yale University. The registered enrollment target is 77 participants, above the 70-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06042517, a NA study of Insulin Sensitivity, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the effect of hepatic ultrasound treatment on changes from baseline in whole-body insulin sensitivity during a hyperinsulinemic, euglycemic clamp (HE Clamp).
Primary Outcome
Insulin Sensitivity calculated as Glucose disposal rate / insulin ratio during steady state (M/I) to evaluate the effect of hepatic ultrasound treatment on changes from baseline in whole-body insulin sensitivity during a hyperinsulinemic, euglycemic clamp (HE Clamp)
Conditions Studied
Interventions
- DEVICE Ultrasound
- DIAGNOSTIC_TEST OGTT with unlabeled glucose and liver NMR
- DIAGNOSTIC_TEST OGTT with carbon-13 labeled glucose and liver NMR
- DIAGNOSTIC_TEST CGM glucose reading
- DIAGNOSTIC_TEST HEC - Hyperinsulinemic-Euglycemic-Clamp
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2023-09-30 |
| Est. Completion | 2027-09-30 |
| Phase | NA |
What NCT06042517 shows while recruiting
NCT06042517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, above the 70-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Insulin Sensitivity appearing as the primary indexed condition, and to 5 interventions - of which Ultrasound is the first listed.
NCT06042517 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06042517 about?
NCT06042517 is a clinical study titled "Mechanisms of Ultrasound Neuromodulation Effects in Diabetes". This study aims to evaluate the effect of hepatic ultrasound treatment on changes from baseline in whole-body insulin sensitivity during a hyperinsulinemic, euglycemic clamp (HE Clamp).
What is the current status of trial NCT06042517?
This trial is currently recruiting. It is a NA study. The enrollment target is 77 participants. The study started on 2023-09-30. Estimated completion is 2027-09-30.
What conditions does trial NCT06042517 study?
This clinical trial studies the following conditions: Insulin Sensitivity.
What interventions are being tested in trial NCT06042517?
The interventions under investigation include: Ultrasound (DEVICE), OGTT with unlabeled glucose and liver NMR (DIAGNOSTIC_TEST), OGTT with carbon-13 labeled glucose and liver NMR (DIAGNOSTIC_TEST), CGM glucose reading (DIAGNOSTIC_TEST), HEC - Hyperinsulinemic-Euglycemic-Clamp (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06042517?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06042517 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Sensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06042517's enrollment target sits among peer trials
77 6th of 29 higher than 24 of 29 other Insulin Sensitivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Sensitivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Countermeasures to Circadian Misalignment
RECRUITING · NA
-
Effect of Pulsatile Hormone Administration on Insulin Action
RECRUITING · NA
-
Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition
RECRUITING · NA
-
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI